Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of the International AIDS Society
Published in: Journal of the International AIDS Society 4/2010

Open Access 01-12-2010 | Poster presentation

Reasons for using and efficacy of raltegravir in salvage regimens without protease inhibitors in clinical practice

Authors: JM Llibre, E Martínez, P Barreiro, R Escrig, E Ribera, M Cervantes, A Imaz, F Gutierrez, H Knobel, A Ornelas, FX Zamora, B Clotet

Published in: Journal of the International AIDS Society | Special Issue 4/2010

Login to get access

Excerpt

The efficacy of raltegravir (RAL) in salvage regimens without protease inhibitors (PI) has not been evaluated in randomized trials, and information about its efficacy and reasons for its initiation in cohort studies has received scant attention. In some particular scenarios physicians may be forced to use RAL without PI due to advanced protease resistance, toxicity or patient refusal. …
Metadata
Title
Reasons for using and efficacy of raltegravir in salvage regimens without protease inhibitors in clinical practice
Authors
JM Llibre
E Martínez
P Barreiro
R Escrig
E Ribera
M Cervantes
A Imaz
F Gutierrez
H Knobel
A Ornelas
FX Zamora
B Clotet
Publication date
01-12-2010
Publisher
BioMed Central
DOI
https://doi.org/10.1186/1758-2652-13-S4-P35

Other articles of this Special Issue 4/2010

Journal of the International AIDS Society 4/2010 Go to the issue

Poster presentation

The impact of late presentation: analysis of a cohort of 313 Portuguese patients

Poster presentation

Pharmacokinetic (PK) and pharmacodynamic analyses of once- and twice-daily darunavir/ritonavir (DRV/r) in the ODIN trial

Poster presentation

Therapeutics designed to neutralize soluble HIV tat protein could preserve IL-7 signaling and CD8 T-cell function in HIV+ patients

Poster presentation

Prediction of virological failure in HIV-infected individuals treated with cART in Suriname

Poster presentation

A comparison of the FDA TLOVR and FDA Snapshot algorithms based on studies evaluating once-daily vs. twice daily lopinavir/ritonavir (LPV/r) regimens

Poster presentation

High preterm delivery rates associated with initiation of HAART during pregnancy
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits